Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E30.71 EPS (ttm)2.11 Insider Own0.70% Shs Outstand1.27B Perf Week-0.87%
Market Cap81.90B Forward P/E9.28 EPS next Y6.97 Insider Trans-0.34% Shs Float1.26B Perf Month1.02%
Income2.71B PEG13.93 EPS next Q1.69 Inst Own83.50% Short Float1.11% Perf Quarter0.53%
Sales22.37B P/S3.66 EPS this Y-45.60% Inst Trans0.42% Short Ratio2.32 Perf Half Y-0.68%
Book/sh16.26 P/B3.98 EPS next Y-0.91% ROA4.30% Target Price78.65 Perf Year-10.07%
Cash/sh18.04 P/C3.58 EPS next 5Y2.21% ROE12.40% 52W Range60.32 - 72.90 Perf YTD3.34%
Dividend2.52 P/FCF16.78 EPS past 5Y18.10% ROI12.00% 52W High-11.33% Beta1.13
Dividend %3.90% Quick Ratio2.90 Sales past 5Y14.60% Gross Margin79.60% 52W Low7.16% ATR1.30
Employees11000 Current Ratio3.00 Sales Q/Q0.10% Oper. Margin19.40% RSI (14)49.14 Volatility2.10% 1.80%
OptionableYes Debt/Eq1.19 EPS Q/Q-157.30% Profit Margin12.00% Rel Volume0.61 Prev Close65.38
ShortableYes LT Debt/Eq1.07 EarningsOct 24 AMC Payout116.50% Avg Volume5.99M Price64.64
Recom2.10 SMA20-0.27% SMA500.16% SMA200-1.23% Volume3,673,560 Change-1.13%
Oct-25-19Downgrade Maxim Group Buy → Hold
Oct-17-19Resumed BofA/Merrill Neutral $70
Jul-29-19Upgrade RBC Capital Mkts Outperform → Top Pick $91
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Nov-11-19 01:50PM  Top Research Reports for Toyota, Netflix & AbbVie Zacks
Nov-09-19 04:30PM  New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile Business Wire
Nov-08-19 08:06PM  Did You Invest in Gilead Sciences? Business Wire
08:00AM  Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy Business Wire
08:00AM  Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019 Business Wire
08:00AM  Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019 Business Wire
Nov-07-19 01:54PM  Trump administration sues Gilead Sciences over HIV prevention patents MarketWatch
12:08AM  US sues Gilead over HIV patent infringements Financial Times
Nov-06-19 09:00AM  Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019 Business Wire
06:45AM  Gileads Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials Business Wire
06:45AM  Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP Compared With Truvada For PrEP® Business Wire
Nov-05-19 11:09AM  Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y Zacks
10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Nov-04-19 05:05PM  Biotech ETFs in Focus on Impressive Q3 Earnings Results Zacks
01:14PM  Cambrex Corporation -- Moody's assigns B3 CFR rating to Cambrex Corporation; outlook stable Moody's
Nov-02-19 10:49AM  This Insider Has Just Sold Shares In Gilead Sciences, Inc. (NASDAQ:GILD) Simply Wall St.
Oct-31-19 04:01PM  Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting Business Wire
11:36AM  The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG Zacks
Oct-30-19 10:56AM  Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More Zacks
10:23AM  UPDATE 2-Merck loses bid to revive $2.54 bln patent verdict against Gilead Reuters
08:00AM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
Oct-28-19 11:59AM  Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More Zacks
08:42AM  Don't Sell Gilead Sciences, Inc. (NASDAQ:GILD) Before You Read This Simply Wall St.
08:00AM  Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development Business Wire
Oct-27-19 04:47PM  Stocks That Fell to 3-Year Lows in the Week of Oct. 25 GuruFocus.com
Oct-26-19 12:15AM  Edited Transcript of GILD earnings conference call or presentation 24-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-25-19 03:37PM  4 Top Stock Trades for Monday: TSLA, GILD, GLD, VZ InvestorPlace
01:09PM  2 Large-Cap Stocks Issue Quarterly Figures GuruFocus.com
12:41PM  Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes Benzinga
12:14PM  Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day Zacks
10:36AM  Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat Zacks
09:51AM  Biotech Fund Investors Are Fleeing, but Biogen Stock and Others Are Rising Barrons.com
09:32AM  Gilead Stock Is Down as Wall Street Flags Concerns About Deals and Pipeline of New Drugs Barrons.com
09:20AM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
07:12AM  The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug Benzinga
06:42AM  Gilead Sciences Shares Fall After Third-Quarter Earnings Report TheStreet.com
Oct-24-19 06:37PM  UPDATE 1-Gilead third-quarter results in line, but Yescarta sales dip Reuters
06:10PM  Q3 Earnings Frenzy: Amazon (AMZN), Intel (INTC) & More Zacks
05:15PM  Gilead Sciences (GILD) Misses Q3 Earnings Estimates Zacks
05:03PM  Gilead Stock Dives On Lackluster Sales, Third-Quarter Earnings Miss Investor's Business Daily
04:39PM  Gilead Earnings Meet Expectations, but Stock Falls Barrons.com
04:31PM  Gilead posts third-quarter net loss, sales in line with Street estimates Reuters
04:21PM  Gilead Sciences stock falls after earnings beat, revenue miss MarketWatch
04:06PM  6 High-Yielding Dividend Stocks GuruFocus.com
04:02PM  Gilead Sciences Announces Fourth Quarter 2019 Dividend Business Wire
04:01PM  Gilead Sciences Announces Third Quarter 2019 Financial Results Business Wire
12:06PM  Gilead Earnings Miss, Revenue Inline In Q3 Investing.com
Oct-23-19 05:18PM  Amazon, Twitter, Intel earnings What to know in markets Thursday Yahoo Finance
11:23AM  Why Gilead (GILD) Might Surprise This Earnings Season Zacks
10:58AM  The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences Zacks
10:07AM  Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings? Zacks
Oct-22-19 01:48PM  Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley Zacks
Oct-21-19 11:39AM  Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store? Zacks
11:00AM  What's in Store for Healthcare ETFs in Q3 Earnings? Zacks
Oct-18-19 12:05PM  Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings? Zacks
11:22AM  New Gilead CFO: Let's Make a Deal GuruFocus.com
11:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings? Zacks
10:21AM  Factors Setting the Tone for Novartis' (NVS) Q3 Earnings Zacks
Oct-17-19 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
03:42PM  Job hopping: This is how long employees typically stay at Tesla, Apple, Facebook, Cisco, Nvidia, Oracle and more American City Business Journals
10:54AM  Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings? Zacks
10:34AM  Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-16-19 09:17AM  Biogen (BIIB) to Report Q3 Earnings: What's in the Cards? Zacks
01:35AM  PRESS DIGEST - Wall Street Journal - Oct 16 Reuters
Oct-15-19 03:26PM  Gilead Just Named a New CFO. Is More Deal Making on the Way? Barrons.com
11:57AM  The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar Zacks
08:48AM  Gilead names Andrew Dickinson CFO effective Nov. 1 MarketWatch
08:30AM  Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer Business Wire
Oct-14-19 02:49PM  Top Stock Reports for Cisco, SAP & Gilead Zacks
09:14AM  Why cell therapies are cancer's next frontier American City Business Journals
Oct-11-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
05:10PM  Startup with eye on fatty liver disease NASH lays out $70M IPO plan American City Business Journals
12:49PM  Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment Zacks
10:10AM  Why Gilead (GILD) Could Beat Earnings Estimates Again Zacks
09:19AM  Gilead-Galapagos Report Efficacy & Safety Results on RA Drug Zacks
08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 06:00PM  Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis Business Wire
04:05PM  Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019 Business Wire
Oct-09-19 06:39PM  Do Hedge Funds Love Gilead Sciences, Inc. (GILD)? Insider Monkey
11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
11:10AM  Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan Zacks
Oct-08-19 11:43AM  UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
08:27AM  REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
08:00AM  REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report Reuters
07:11AM  The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration Benzinga
02:00AM  Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan Business Wire
Oct-07-19 09:08AM  Novo Nordisk Focuses on Pipeline Development Amid Competition Zacks
08:40AM  Gilead Sciences names chief medical officer, from Genentech MarketWatch
08:30AM  Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer Business Wire
Oct-04-19 10:45AM  Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion Zacks
08:30AM  Gilead Presents New Data From the Companys HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 Business Wire
Oct-03-19 05:59PM  UPDATE 1-U.S. FDA approves Gilead's Descovy for HIV prevention Reuters
05:50PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
03:32PM  U.S. FDA approves Gilead's HIV prevention treatment Reuters
02:49PM  U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP) Business Wire
Oct-01-19 02:59PM  Forget FAANG, investors should consider MANG Yahoo Finance
07:36AM  Did You Manage To Avoid Gilead Sciences's (NASDAQ:GILD) 40% Share Price Drop? Simply Wall St.
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
12:38PM  Ariel Investments' Rupal Bhansali: Growth is working, but it's time to switch to value' Yahoo Finance Video
Sep-29-19 09:15PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 27 GuruFocus.com
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; Lyndra Therapeutics; Carna Biosciences Inc.; and Glympse Bio, Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM